Every material Form 8-K Vivos Therapeutics, Inc. has filed with the SEC since October 15, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Nasdaq's Listing Qualifications staff said on October 20, 2026 that Vivos Therapeutics now meets the $2.5 million minimum stockholders' equity requirement, based on the company's October 19, 2026 8-K. The company said the SOD transaction, which included issuing Series C Convertible Preferred Stock, drove the improvement, but Nasdaq said the company could still face delisting if it does not show compliance in its next periodic report, and the preferred stock is convertible into up to 80,000,000 common shares, which could dilute existing holders.
Nasdaq letter dated October 20, 2026 says Vivos complies with the $2.5 million stockholders' equity minimum under Listing Rule 5550(b)(1).
Series C Convertible Preferred Stock with an aggregate stated value of $12,000,000 was issued as part of the SOD Sciences transaction, and is expected to increase stockholders' equity by more than $10 million.
Preferred stock converts at $0.15 per share into up to 80,000,000 common shares, subject to a 19.99% exchange cap pending stockholder approval.
Nasdaq said the company may be delisted if it does not evidence compliance upon filing its next periodic report.
Vivos Therapeutics closed on October 16, 2026 its acquisition of an 11% fully diluted stake in SOD Sciences and a 50% co-ownership interest in SOD's pseudohypoxia early-warning test, paying with 12,000 shares of newly created Series C Convertible Preferred Stock and no cash. The preferred converts at $0.15 per share into up to 80,000,000 common shares, which could dilute existing holders, and the company expects the deal to raise stockholders' equity by more than $10 million, which it says may restore compliance with a Nasdaq minimum.
Closed October 16, 2026: 3,057,879 SOD common shares (at least 11% fully diluted) plus a 50% interest in the test and related IP, for 12,000 Series C Preferred with a $12,000,000 aggregate stated value; no cash paid.
Series C converts at $0.15 per share into up to 80,000,000 common shares; until stockholder approval, conversions are capped at 6,718,517 shares, against 33,609,393 common shares outstanding before the signing.
Vivos expects stockholders' equity to rise by more than $10 million, citing $10,380,000 of expected additional equity, and believes this restores compliance with Nasdaq's $2.5 million stockholders' equity requirement, subject to Nasdaq revi
Commercial benefits depend on definitive agreements with AHA, which is in bankruptcy proceedings, and Cleveland Clinic Weston, neither of which had been executed as of the filing.
Vivos Therapeutics agreed to issue 12,000 shares of a new Series C Convertible Preferred Stock, with a $12 million aggregate stated value and no cash paid, to acquire at least an 11% fully diluted stake in SOD Sciences and a 50% co-ownership interest in SOD's pseudohypoxia test. The preferred converts at a fixed $0.15 per share into up to 80 million common shares, which could dilute existing stockholders, while the company says the deal could raise reported stockholders' equity and help its Nasdaq compliance efforts. Closing is expected on October 15, 2026, subject to conditions including auditor concurrence and a consent from Streeterville Capital.
Vivos will issue 12,000 Series C Convertible Preferred shares with a $12 million aggregate stated value; no cash is paid by either party.
In exchange, Vivos receives 2,907,338 SOD common shares (at least 11% fully diluted) and an undivided 50% co-ownership interest in the test.
Preferred converts at a fixed $0.15 per share into up to 80,000,000 common shares; a 19.99% exchange cap applies pending stockholder approval.
Closing is expected on or about October 15, 2026, subject to conditions including Streeterville Capital's consent and Nasdaq notification.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Vivos Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →